Bioinspired and bioderived nanomedicine for inflammatory bowel disease.

Gazzi, Rafaela; Gelli, Rita; Aleandri, Simone; Carone, Marianna; Luciani, Paola (2024). Bioinspired and bioderived nanomedicine for inflammatory bowel disease. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 16(4), e1986. Wiley 10.1002/wnan.1986

Preview

Text WIREs_Nanomed_Nanobiotechnol_-_2024_-_Gazzi_-_Bioinspired_and_bioderived_nanomedicine_for_inflammatory_bowel_disease.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (5MB) | Preview

Due to its chronic nature and complex pathophysiology, inflammatory bowel disease (IBD) poses significant challenges for treatment. The long-term therapies for patients, often diagnosed between the ages of 20 and 40, call for innovative strategies to target inflammation, minimize systemic drug exposure, and improve patients' therapeutic outcomes. Among the plethora of strategies currently pursued, bioinspired and bioderived nano-based formulations have garnered interest for their safety and versatility in the management of IBD. Bioinspired nanomedicine can host and deliver not only small drug molecules but also biotherapeutics, be made gastroresistant and mucoadhesive or mucopenetrating and, for these reasons, are largely investigated for oral administration, while surprisingly less for rectal delivery, recommended first-line treatment approach for several IBD patients. The use of bioderived nanocarriers, mostly extracellular vesicles (EVs), endowed with unique homing abilities, is still in its infancy with respect to the arsenal of nanomedicine under investigation for IBD treatment. An emerging source of EVs suited for oral administration is ingesta, that is, plants or milk, thanks to their remarkable ability to resist the harsh environment of the upper gastrointestinal tract. Inspired by the unparalleled properties of natural biomaterials, sophisticated avenues for enhancing therapeutic efficacy and advancing precision medicine approaches in IBD care are taking shape, although bottlenecks arising either from the complexity of the nanomedicine designed or from the lack of a clear regulatory pathway still hinder a smooth and efficient translation to the clinics. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

Interest & Impact

Downloads

0 since deposited on 15 Aug 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item